Lisa Jaubert, MD
Interventional Pain Medicine · Covington, LANPI 1144410796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 26.4% of the total. Reporting peaked in 2021 at $254 and has fallen 81.7% since, to $47 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in LA, where the typical reported total is $4,761.
Across 31 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$138
- Lilly USA, LLC$53
- Neurelis, Inc.$50
- Zyla Life Sciences, Inc.$42
- Boston Scientific$30
- Biohaven Pharmaceuticals, Inc.$30
- plus $182 from 9 others
What the payments were for
- Food & beverage$524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 8 | $138 |
| Lilly USA, LLC | 4 | $53 |
| Neurelis, Inc. | 3 | $50 |
| Zyla Life Sciences, Inc. | 2 | $42 |
| Boston Scientific | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Biotronik NRO, Inc. | 1 | $28 |
| Novartis | 1 | $22 |
| Relievant Medsystems, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $20 |
| Abbott | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Stimwave Technologies Incorporated | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$524 in reported general payments places this provider in the 10th percentile of 57 interventional pain medicine providers in Louisiana.
See all interventional pain medicine providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 40 | $393 |
| Pregabalin | 13 | $119 |
| Cyclobenzaprine Hcl | 20 | $85 |
| Atorvastatin Calcium | 14 | $48 |
| Amlodipine Besylate | 11 | $8 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Covington
- Richard RobertsonCovington$6K
- Allan ParrCovington$5K
- Ronald SeguraCovington$4K
- Chad DomangueCovington$1K
- Donald RichardsonCovington$1K
- Maged GuirguisNew Orleans$565K
- Suneil JollyKenner$107K
- John CefaluShreveport$71K
- Steve LeeSlidell$57K
- William WhyteShreveport$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.